Can Tissue-Based Immune Markers be Used for Studying the Natural History of Cancer?

Annals of Epidemiology

Volumn 22, Issue 7, 2012, Pages 520-530

  Koshiol, Jill ^a   Lin, Shih Wen ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD28 ANTIGEN; CD33 ANTIGEN; CD57 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; EOTAXIN 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL POPULATION; CYTOKINE RELEASE; DISEASE MARKER; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NEOPLASM; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE SIZE; STUDY DESIGN; TH1 CELL; TH17 CELL; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

BIOLOGICAL MARKERS; HUMANS; MOLECULAR EPIDEMIOLOGY; NEOPLASMS; RESEARCH DESIGN;

EID: 84861928321     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2012.03.001     Document Type: Note

References (93)

1. Burnet M. Cancer: a biological approach. Br Med J 1957, 1:779-786.
2. Schulz T.F. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009, 125:1755-1763.
3. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
4. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
5. Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C., Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093-1102.
6. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011, 1:54-67.
7. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
8. Milne K., Köbel M., Kalloger S.E., Barnes R.O., Gao D., Gilks C.B., et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009, 4:e6412.
9. Johnson S.K., Kerr K.M., Chapman A.D., Kennedy M.M., King G., Cockburn J.S., et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000, 27:27-35.
10. Ladányi A., Kiss J., Somlai B., Gilde K., Fejos Z., Mohos A., et al. Density of DC-LAMP+ dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007, 56:1459-1469.
11. Yang X.R., Chang-Claude J., Goode E.L., Couch F.J., Nevanlinna H., Milne R.L., et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium Studies. J Natl Cancer Inst 2010, 103:250-263.
12. Ogino S., Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010, 102:365-367.
13. Nosho K., Baba Y., Tanaka N., Shima K., Hayashi M., Meyerhardt J.A., et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010, 222:350-366.
14. Febbo P.G., Ladanyi M., Aldape K.D., De Marzo A.M., Hammond M.E., Hayes D.F., et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011, 9(Suppl 5):S1-32.
15. PR2085a. High-density (114 cases/208 cores) prostate adenocarcinoma (I-4 grade) and normal prostate (from autopsy and cancer adjacent) tissue array. Available from: . Accessed July 7, 2011. http://www.biomax.us/tissue-arrays/Prostate/PR2085a.
16. Tissue array networks. Available from: . Accessed July 23, 2011. http://www.tissue-array.net/.
17. Zamarron B.F., Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011, 7:651-658.
18. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896.
19. Movahedi K., Laoui D., Gysemans C., Baeten M., Stangé G., Van den Bossche J., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from ly6c(high) monocytes. Cancer Res 2010, 70:5728-5739.
20. Krausgruber T., Blazek K., Smallie T., Alzabin S., Lockstone H., Sahgal N., et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011, 12:231-238.
21. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
22. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
23. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
24. Condamine T., Gabrilovich D.I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011, 32:19-25.
25. Chen W., Jin W., Hardegen N., K-j Lei, Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
26. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
27. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
28. Schumacher K., Haensch W., Röefzaad C., Schlag P.M. Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res 2001, 61:3932-3936.
29. Haas M., Dimmler A., Hohenberger W., Grabenbauer G., Niedobitek G., Distel L. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 2009, 9:65.
30. Kobayashi A., Greenblatt R.M., Anastos K., Minkoff H., Massad L.S., Young M., et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004, 64:6766-6774.
31. Kovacic M.B., Katki H.A., Kreimer A.R., Sherman M.E. Epidemiologic analysis of histologic cervical inflammation: relationship to human papillomavirus infections. Human Pathol 2008, 39:1088-1095.
32. Nedergaard B.S., Nielsen K., Nyengaard J.R., Ladekarl M. Stereologic estimation of the total numbers, the composition and the anatomic distribution of lymphocytes in cone biopsies from patients with stage I squamous cell carcinoma of the cervix uteri. APMIS 2007, 115:1321-1330.
33. Shen Z., Zhou S., Wang Y., R-l Li, Zhong C., Liang C., et al. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol 2010, 136:1585-1595.
34. Brennan D., Gallagher W. Prognostic ability of a panel of immunohistochemistry markers-retailoring of an 'old solution'. Breast Cancer Res 2008, 10:102.
35. Brennan M.-L., Penn M.S., Van Lente F., Nambi V., Shishehbor M.H., Aviles R.J., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1604.
36. Whitcup S.M., Belfort R., de Smet M.D., Palestine A.G., Nussenblatt R.B., Chan C- C. Immunohistochemistry of the inflammatory response in Propionibacterium acnes endophthalmitis. Arch Ophthalmol 1991, 109:978-979.
37. Cregger M., Berger A.J., Rimm D.L. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 2006, 130:1026-1030.
38. Brennan D.J., O'Connor D.P., Rexhepaj E., Ponten F., Gallagher W.M. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 2010, 10:605-617.
39. Bordeaux J., Welsh A., Agarwal S., Killiam E., Baquero M., Hanna J., et al. Antibody validation. Biotechniques 2010, 48:197-209.
40. Beranek J.T. CD68 is not a macrophage-specific antigen. Ann Rheum Dis 2005, 64:342-344.
41. Camp R.L., Neumeister V., Rimm D.L. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008, 26:5630-5637.
42. Dahlman A., Rexhepaj E., Brennan D.J., Gallagher W.M., Gaber A., Lindgren A., et al. Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Mod Pathol 2011, 24:708-719.
43. Moeder C.B., Giltnane J.M., Moulis S.P., Rimm D.L. Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol 2009, 520:163-175.
44. Prendergast G.C., Chang M.Y., Mandik-Nayak L., Metz R., Muller A.J. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 2011, 18:2257-2262.
45. Chen T., Jin R., Huang Z., Hong W., Chen Z., Wang J. The variation of expression of CD4+ CD25+ Foxp3+ regulatory T cells in patients with Helicobacter pylori infection and eradication. Hepatogastroenterology 2010, 57:430-435.
46. Yuan X.L., Chen L., Li M.X., Dong P., Xue J., Wang J., et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin Immunol 2010, 134:277-288.
47. Wilson E.B., Brooks D.G. The role of IL-10 in regulating immunity to persistent viral infections. Curr Top Microbiol Immunol 2011, 350:39-65.
48. Weng N.P., Akbar A.N., Goronzy J. CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol 2009, 30:306-312.
49. Fowler D.W., Copier J., Wilson N., Dalgleish A.G., Bodman-Smith M.D. Mycobacteria activate gammadelta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother 2011 Oct 15, [Epub ahead of print].
50. Hofmeyer K.A., Jeon H., Zang X. The PD-1/PD-L1 (B7-H1) Pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J Biomed Biotechnol 2011, 2011:451694.
51. Engels E.A. Cancer risk associated with receipt of vaccines contaminated with simian virus 40: epidemiologic research. Expert Rev Vaccines 2005, 4:197-206.
52. Koshiol J., Kreimer A.R. Lessons from Australia: human papillomavirus is not a major risk factor for esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2010, 19:1889-1892.
53. Koshiol J., Wang E., Zhao Y., Marincola F., Landi M.T. Strengths and limitations of laboratory procedures for microRNA detection. Cancer Epidemiol Biomarkers Prev 2010, 19:907-911.
54. Rothman K.J., Greenland S., Lash T.L. Modern epidemiology 2008, Lippincott Williams & Wilkins, Philadelphia. 3rd ed.
55. Landgren O., Kyle R.A., Pfeiffer R.M., Katzmann J.A., Caporaso N.E., Hayes R.B., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
56. Herrero R., Schiffman M.H., Bratti C., Hildesheim A., Balmaceda I., Sherman M.E., et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1997, 1:362-375.
57. Safaeian M, Hildesheim A, Gonzalez P, Yu K, Porras C, Li JQ, et al. Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer. PLoS ONE (accepted).
58. Wang S.S., Zuna R.E., Wentzensen N., Dunn S.T., Sherman M.E., Gold M.A., et al. Human Papillomavirus Cofactors by Disease Progression and Human Papillomavirus Types in the Study to Understand Cervical Cancer Early Endpoints and Determinants. Cancer Epidemiol Biomarkers Prev 2009, 18:113-120.
59. Wentzensen N., Schiffman M., Dunn S.T., Zuna R.E., Walker J., Allen R.A., et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer 2009, 124:964-969.
60. Hollander M., Wolfe D.A. Nonparametric statistical methods 1999, John Wiley & Sons, New York. 2nd ed.
61. Anderson W.F., Pfeiffer R.M., Dores G.M., Sherman M.E. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2006, 15:1899-1905.
62. Anderson W.F., Rosenberg P.S., Menashe I., Mitani A., Pfeiffer R.M. Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst 2008, 100:1804-1814.
63. Grubeck-Loebenstein B., Wick G. The aging of the immune system. Adv Immunol 2002, 80:243-284.
64. Forbes M.R. On sex differences in optimal immunity. Trends in Ecology & Evolution 2007, 22:111-113.
65. Lichtman M.A., Vaughan J.H., Hames C.G. The distribution of serum immunoglobulins, anti-gamma-G globulins (" rheumatoid factors" ) and antinuclear antibodies in White and Negro subjects in Evans County, Georgia. Arthritis Rheum 1967, 10:204-215.
66. Mili F., Flanders W.D., Boring J.R., Annest J.L., Destefano F. The associations of race, cigarette smoking, and smoking cessation to measures of the immune system in middle-aged men. Clin Immunol Immunopathol 1991, 59:187-200.
67. Tollerud D.J., Brown L.M., Blattner W.A., Weiss S.T., Maloney E.M., Kurman C.C., et al. Racial differences in serum immunoglobulin levels: relationship to cigarette smoking, T-cell subsets, and soluble interleukin-2 receptors. J Clin Lab Anal 1995, 9:37-41.
68. de-The G., Day N.E., Geser A., Lavoue M.F., Ho J.H., Simons M.J., et al. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review. IARC Sci Publ 1975, 3-16.
69. Piruzyan L., Mikhailovskii E. Metabolic, ethnic, constitutional specificity of antibacterial immunity. Human Physiol 2009, 35:357-368.
70. Wallace T.A., Martin D.N., Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 2011, 32:1107-1121.
71. Szabo G., Mandrekar P. A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res 2009, 33:220-232.
72. Anderson B.L., Cu-Uvin S. Clinical parameters essential to methodology and interpretation of mucosal responses. Am J Reprod Immunol 2011, 65:352-360.
73. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
74. Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., Smith J.S. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168:123-137.
75. Dawsey S.M., Lewin K.J., Liu F.S., Wang G.Q., Shen Q. Esophageal morphology from Linxian, China. Squamous histologic findings in 754 patients. Cancer 1994, 73:2027-2037.
76. Dawsey S.M., Lewin K.J., Wang G.-Q., Liu F.-S., Nieberg R.K., Yu Y., et al. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. Cancer 1994, 74:1686-1692.
77. Wang G.-Q., Abnet C.C., Shen Q., Lewin K.J., Sun X.-D., Roth M.J., et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut 2005, 54:187-192.
78. Milne A., Carneiro F., O'Morain C., Offerhaus G. Nature meets nurture: molecular genetics of gastric cancer. Human Genetics 2009, 126:615-628.
79. Macarthur M., Hold G.L., El-Omar E.M. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004, 286:G515-G520.
80. Rothman N., Skibola C.F., Wang S.S., Morgan G., Lan Q., Smith M.T., et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006, 7:27-38.
81. Hsing A.W., Sakoda L.C., Rashid A., Andreotti G., Chen J., Wang B.S., et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Res 2008, 68:6442-6452.
82. Wang S.S., Abdou A.M., Morton L.M., Thomas R., Cerhan J.R., Gao X., et al. Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood 2010, 115:4820-4823.
83. Wang S.S., Hildesheim A. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003, 35-40.
84. Landi M.T., Dracheva T., Rotunno M., Figueroa J.D., Liu H., Dasgupta A., et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 2008, 3:e1651.
85. Rotunno M., Hu N., Su H., Wang C., Goldstein A.M., Bergen A.W., et al. A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma. Cancer Prev Res (Phila) 2011, 4:1599-1608.
86. Chaturvedi A.K., Kemp T.J., Pfeiffer R.M., Biancotto A., Williams M., Munuo S., et al. Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol Biomarkers Prev 2011, 20:1902-1911.
87. Löb S., Königsrainer A., Zieker D., Brücher B., Rammensee H.-G., Opelz G., et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009, 58:153-157.
88. Ruffell B., DeNardo D.G., Affara N.I., Coussens L.M. Lymphocytes in cancer development: Polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 2010, 21:3-10.
89. Neumeister V., Agarwal S., Bordeaux J., Camp R.L., Rimm D.L. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 2010, 176:2131-2138.
90. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007, 104:3360-3365.
91. Nagaraj S., Gabrilovich D.I. Myeloid-derived suppressor cells in human cancer. Cancer J 2010, 16:348-353.
92. Junankar S.R., Eichten A., Kramer A., de Visser K.E., Coussens L.M. Analysis of immune cell infiltrates during squamous carcinoma development. J Investig Dermatol Symp Proc 2006, 11:36-43.
93. Brant R. Inference for means: Comparing two independent samples. Available from: . http://www.stat.ubc.ca/~rollin/stats/ssize/n2.html.